Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-11
2006-07-11
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S279000, C544S266000, C544S248000
Reexamination Certificate
active
07074799
ABSTRACT:
Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
REFERENCES:
patent: 4424205 (1984-01-01), LaHann et al.
patent: 4681897 (1987-07-01), Brand
patent: 4812446 (1989-03-01), Brand
patent: 5021450 (1991-06-01), Blumberg
patent: 5064833 (1991-11-01), Ife et al.
patent: 5290816 (1994-03-01), Blumberg
patent: 5420135 (1995-05-01), Brown et al.
patent: 5580870 (1996-12-01), Barker et al.
patent: 5616582 (1997-04-01), Barker
patent: 5654307 (1997-08-01), Bridges et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5801183 (1998-09-01), Keana et al.
patent: 5814630 (1998-09-01), Barker et al.
patent: 5840720 (1998-11-01), Chen
patent: 5866572 (1999-02-01), Barker et al.
patent: 5939421 (1999-08-01), Palanki et al.
patent: 5962532 (1999-10-01), Campbell et al.
patent: 6030969 (2000-02-01), Bhagwat et al.
patent: 6084095 (2000-07-01), Bridges et al.
patent: 6169091 (2001-01-01), Cockerill et al.
patent: 6174889 (2001-01-01), Cockerill et al.
patent: 6207669 (2001-03-01), Cockerill et al.
patent: 6225318 (2001-05-01), Sobolov-Jaynes et al.
patent: 6248771 (2001-06-01), Shenoy et al.
patent: 6248788 (2001-06-01), Robbins et al.
patent: 6251912 (2001-06-01), Wissner et al.
patent: 6391874 (2002-05-01), Cockerill et al.
patent: 6395733 (2002-05-01), Arnold et al.
patent: 6399602 (2002-06-01), Barker et al.
patent: 6413971 (2002-07-01), Arnold et al.
patent: 6437147 (2002-08-01), Andersen et al.
patent: 6476076 (2002-11-01), Lee et al.
patent: 6723730 (2004-04-01), Bakthavatchalam et al.
patent: 2003/0133951 (2003-07-01), Coe et al.
patent: 1 229 025 (2002-08-01), None
patent: WO 89/05297 (1989-06-01), None
patent: WO 95/15758 (1989-06-01), None
patent: WO 96/09294 (1996-03-01), None
patent: WO 96/15118 (1996-05-01), None
patent: WO 96/40142 (1996-12-01), None
patent: WO 97/13771 (1997-04-01), None
patent: WO 95/19774 (1997-08-01), None
patent: WO 98/02437 (1998-01-01), None
patent: WO 98/23613 (1998-06-01), None
patent: WO 98/46605 (1998-10-01), None
patent: WO-99/00115 (1999-01-01), None
patent: WO 99/35146 (1999-07-01), None
patent: WO 00/23444 (2000-04-01), None
patent: WO 01 04111 (2001-01-01), None
patent: WO 01/21594 (2001-03-01), None
patent: WO 01/21595 (2001-03-01), None
patent: WO 01/21596 (2001-03-01), None
patent: WO 01/21597 (2001-03-01), None
patent: WO-01/85158 (2001-11-01), None
patent: WO-02/16317 (2002-02-01), None
patent: WO-02/16318 (2002-02-01), None
patent: WO-02/16319 (2002-02-01), None
patent: WO 02/22601 (2002-03-01), None
patent: WO-02/072536 (2002-09-01), None
patent: WO-02/076946 (2002-10-01), None
patent: WO-02/076946 (2002-10-01), None
patent: WO-02/090326 (2002-11-01), None
patent: WO 03/014064 (2003-02-01), None
patent: WO 03/018029 (2003-03-01), None
Temple et al., (1968) J. Medicinal Chem. 11:1216-1218.
Abbadie et al. (1994) J. Neurosci. 14(10):5865-5871.
Aguayo and White (1992) Brain Research 570:61-67.
Bennett and Xie (1988) Pain 33:87-107.
Bertorelli et al. (1999) Br. J. Pharmacol. 128(6):1252-1258.
Carpenter et al. (1979) J. Biol. Chem. 254:4884-4891.
Wu et al., “Multiple Sensory and Functional Effects of Non-Phenolic Aminodimethylene Nonivamide: An Approach to Capsaicin Antagonist,” Gen. Pharmac. 27:151-158 (1996).
Urban et al., “In vivo pharmacology of SDZ 249-665, a novel, non-pungent capsaicin analogue,” Pain 89:65-74 (2000).
Ohkubo et al., “The Selective Capsaicin Antagonist Capsazepine Abolishes the Antiociceptive Action of Eugnol and Guaiacol,” J, Dent. Res. 76:848-851 (1997).
Santos et al., “Ruthenium red and capsazepine antinociceptive effect in formalin and capsaicin models of pain in mice,” Neuroscience Letters 235:73-76 (1997).
Kwak et al., “A Capsaicin-Receptor Antagonist, Capsazepine, Reduces Inflammation-Induced Hyperalgesic Responses in the Rat: Evidence For An Endogenous Capsaicin-Like Substance,” Neuroscience 86:619-626 (1998).
Szallasi et al., “Vanilloid (Capsaicin) Receptors and Mechanisms,” Pharmacological Reviews 1:159-211 (1999).
Bevan et al., “Capsazepine: a competitive antagonist of the sensory neuorones excitant capsaicin,”Br. J. Pharmacol. 107:544-552 (1992).
Dickenson et al., “Selective antagonism of capsaicin by capsazepine: evidence for a spinal receptor site in capsaicin-induced antinociception,” Br. J. Pharmacol. 104:1045-1049 (1991).
Caterina et al., “Impaired Nociception and Pain Sensation in Mice Lacking the Capsaicin Receptor,” Science 288:306-313 (2000).
Szallasi et al., “Vanilloid Receptor Ligands,” Drugs and Aging 18:561-573 (2001).
Liu et al., “Capsazepine, a vanilloid receptor antagonist, inhibits nicotinic acetylcholine receptors in rat trigeminal ganglia,” Neuroscience Letters 228:29-32 (1997).
Nagy et al. {European Journal of Pharmacology 500 (2004), 351-369}.
Szallasi et al., {Journal of Medicinal Chemistry, (2004), vol. 47, No. 11, 2717-2723}.
Bakthavatchalam Rajagopal
Blum Charles A.
Brielmann Harry
Caldwell Timothy M.
De Lombaert Stephane
Alexander John B.
Corless Peter F.
Edwards Angell Palmer & & Dodge LLP
Habte Kahsay
Neurogen Corporation
LandOfFree
Substituted quinazolin-4-ylamine analogues does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted quinazolin-4-ylamine analogues, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted quinazolin-4-ylamine analogues will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3598996